U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07169552) titled 'HC010 in First-line PD-L1 Positive Advanced NSCLC Patients' on Aug. 26.
Brief Summary: Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS >=1%)
Study Start Date: Sept. 15
Study Type: INTERVENTIONAL
Condition:
NSCLC
Intervention:
DRUG: HC010
HC010 Q3W intravenous infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: HC Biopharma Inc.
Disclaimer: Curated by HT Syndication....